GLAS supports acquisition of FairJourney Biologics

GLAS is pleased to support Partners Group, acting on behalf of its clients, with the financing for the successful acquisition of a majority stake in FairJouney Biologics, a leading antibody discovery Contract Research Organisation (CRO).

The acquisition will allow Partners Group to work closely with the FairJourney team to expand its technology and capabilities to unlock more effective drug development for its partners.

The GLAS team in Spain handled the transaction in which GLAS acted as both Agent and Security Agent.

About GLAS

GLAS was established in 2011 as an independent provider of institutional debt administration services. The company was originally created to provide the market a willing participant in complex loan restructuring transactions where many large institutions are reluctant to take swift and cooperative action. It offers a wide range of administration services developed specifically for the debt market.

GLAS is recognised as the premier independent, non-creditor, conflict-free provider of loan agency and bond trustee services, with excess of $450bn of assets under administration on a daily basis. For more information, please contact media@glas.agency.